A 48-year-old from Suffolk County is one of over 30 people suing Ozempic's manufacturer for partial loss of vision.

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, ...

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk ... according to Bloomberg Intelligence, with Denmark’s economy set to grow above the European ...

He’s the CEO of Danish pharmaceutical firm Novo Nordisk — best known as the maker of Ozempic and Wegovy, the blockbuster diabetes and weight-loss drugs-turned-cultural phenomena that have ...

Ozempic got US approval in 2017 ... "This is the largest ever." In 2023 Denmark ranked among Europe's fastest-growing economies, as GDP expanded by 2.5%, and half of that was driven by the ...

Could Ozempic be overtaken ... phones and Nokia has retreated to mostly providing back-end technology. For Denmark that would be an economic problem, but for the world the prospect of better ...

Denmark is home to Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, two of the most in-demand drugs in the U.S. for weight loss and diabetes treatment. With demand for those drugs ...